InSilicoTrials is the first cloud-based platform that provides healthcare companies and researchers with easy-to-use tools to perform computational modeling and simulation in pharmaceutical and medical devices development

How does it work?

The platform offers users two computational options:

  • to select the model of choice from the digital library
  • to develop or to upload their own model

The platform enables users to input parameters of choice into the model. For a model from the digital library, parameters choices are guided by best practice ranges.
Simulations are launched and run on protected and secured Microsoft Azure Cloud computing resources.
Completion of the modeling and simulation is notified to the users via e-mail.
The platform enables users to view and analyze the modeling and simulation results and to optimize modeling and simulation scenario’s depending on objectives.

QT/TdP Risk Screen

Drug compounds that primarily affect the slow and the fast components of the delayed rectifier current (IKs and IKr, respectively) and the L-type calcium current (ICaL) channels are good candidates for proarrhythmic disorders.

The QT/TdP Risk Screen tool can be used to estimate the proarrhythmic potential risk of drug compounds in preclinical development.

The tool is based on simulations that predict how different compounds affect the action potential duration (APD) of isolated endocardial, midmyocardial, and epicardial cells as well as the QT interval in a virtual tissue. Multiple channel−drug interactions and state-of-the-art human ventricular action potential models (O’Hara, T., et al. 2011) were used to perform 206.766 cellular and 7072 tissue simulations by blocking the IKs, IKr, and ICaL channels at different concentration levels.

The QT/TdP Risk Screen tool’s performance was validated by classifying the proarrhythmic risk of 84 known compounds, 40 of which torsadogenic. Based on these results the new proarrhythmic risk index Tx was developed, and Tx threshold criteria were identified for cellular endocardial, midmyocardial, and epicardial APDs and for the QT interval (Romero et al. 2018).

The tool is easy to use since it only requires the compound’s in vitro IC50 values towards the IKs, IKr and ICaL ion channels and the compound’s test concentration values for which a proarrhythmic potential risk needs to be assessed.

The QT/TdP Risk Screen tool will help you to spot proarrhythmic risks and to identify a safe concentration range for your compounds.

NuMRis

NuMRis is the tool of the InSilicoMRI library for the investigation of the radiofrequency (RF)-induced heating of passive devices in a MRI scanner.

One of the possible risks posed to a patient with implanted devices during MRI is that conductive structures may pick up RF-energy during the exposure, and locally deposit it as heating in tissue near the implant. To assess the compatibility level, the manufacturer of the medical device has to perform tests to predict the hazard in the worst-case exposure scenario. NuMRis is designed to study the MRI compatibility, for different exposure conditions, of implantable devices (e.g. stents) with different dimensions, configurations or designs. The user can choose to upload his own device or chose a simplified geometry form the tool library.

NuMRis has been implemented in collaboration with the FDA and ANSYS to support the broadening use of computer modeling and simulation for electromagnetic safety analysis prior to a medical device submission. The models of the RF exposure system used in the simulation were provided by the Center for Devices and Radiological Health within the U.S. Food and Drug Administration (FDA-CDRH). The simulation steps are designed to replicate the ASTM F2182-11a Standard.

Software

InSilicoTrials enables you to run the model of your choice with widely adopted software in a pre-configured and integrated framework, and you pay what you use. Engineers, designers, researchers, clinicians use our technological solutions for product design, development, testing and decision making.

ANSYS, the global leader in engineering simulation, provides engineering simulation software to help customers solve the most complex design challenges and engineer successful, innovative products faster and at lower cost.

Cloud

InSilicoTrials allows you to run your simulations on scalable and on-demand computing resources, tailored on your modeling needs.
The cloud-based computational hub is conform to global standards and grants data protection and cybersecurity.

Azure offers a platform to develop solutions for in silico medicine and personalized healthcare, providing on-demand compute resources that enable to run large parallel and batch compute jobs in the cloud.